sales@reportocean.com (Bussiness Sales)
+18882123539 (Us - Toll Free)
+919997112116 (Rest Of World)
Antibody Fragments Market Share, Size, Trends, Industry Analysis Report, By Specificity (Monoclonal, Polyclonal); By Type (FAB, scFv); By Therapy; By Application; By Region; Segment Forecast, 2022 - 2030

Antibody Fragments Market Share, Size, Trends, Industry Analysis Report, By...

Home / Categories / Other
Antibody Fragments Market Share, Size, Trends, Industry Analysis Report, By Specificity (Monoclonal, Polyclonal); By Type (FAB, scFv); By Therapy; By Application; By Region; Segment Forecast, 2022 - 2030
Antibody Fragments Market Share, Size,...
Report Code
RO14/128/2600

Publish Date
30/Sep/2022

Pages
200
PRICE
$ 4904/-
This is a single user license, allowing one specific user access to the product. The product is a PDF.
$ 5483/-
This is a 1-5 user license, allowing up to five users have access to the product. The product is a PDF.
$ 8796/-
This is an enterprise license, allowing all employees within your organization access to the product. The product is a PDF..
The global antibody fragments market size was US$ 7.1 billion in 2021. The global antibody fragments market is expected to grow to US$ 10.9 billion by 2030 and is expected to grow at a CAGR of 5.8% during the forecast period from 2022 to 2030.

Factors Influencing the Market
The pharmaceutical industry is growing at a rapid pace due to the rising prevalence of immunodeficiency. Therefore, the demand for the disease treatment will grow, which will present potential prospects for market growth during the analysis period. The antibody fragments are smaller in size and are more specific, stable, and potent. Additionally, the rising number of cancer cases will also upsurge the demand for antibody fragments in the coming years. full-length antibodies. The use of antibody-based therapeutics has shown promising results in the treatment of cancer. The American Cancer Society report as of 2022 stated that around 1.9 million new cases of cancer were discovered in the U.S., which are expected to result in 609,360 deaths.
However, the partial penetration of the antibody-drug conjugate in the tumor may limit the growth of the market during the analysis period.

Regional Analysis
North America is expected to hold the largest market for antibody fragments, owing to the presence of a large number of regional players, such as Pfizer Inc., Genentech, Inc., etc. Additionally, the growing demand for advanced technology and healthcare infrastructural improvement will all contribute to the growth of the market during the analysis period.
The Asia-Pacific antibody fragments market is expected to grow at the fastest growth rate owing to the rising geriatric population, growing knowledge about medical tourism among people, and research and development in emerging economies like India and China. Therefore, all of these factors will contribute to the growth of the antibody fragments market during the analysis period.

COVID-19 Impact Analysis
The COVID-19 pandemic positively influenced the antibody fragments market as various studies found that antibody fragments can neutralize the effect of the COVID-19 virus. various studies. For instance, the researchers from Karolinska Institute in Sweden published a study in 2020 stating that antibody fragments can efficiently neutralize the effect of COVID-19 virus. Additionally, a research article published in Feb 2022 derived that inhalable antibody fragments can potentially neutralize SARS-CoV-2 variants for COVID-19 therapy.

Competitors in the Market
The prominent industry players profiled in the report are
Pfizer Inc.
Ablynx
Novartis AG
Genentech, Inc.
AbbVie Inc.
Bristol-Myers Squibb Company
Johnson & Johnson Private Limited
Eli Lilly
F. Hoffmann-La Roche AG
Amgen Inc.
The Takeda Pharmaceutical Company Limited
Sanofi S.A.
Biogen Inc.
Other Prominent Players

Market Segmentation
The global antibody fragments market segmentation focuses on Specificity, Type, Therapy, Application, and Region.
By Specificity
Monoclonal Antibodies
Polyclonal Antibodies
By Type
FAB
scFv
sdAb
Others
By Therapy
Monoclonal Antibodies
PAB
Pipeline
By Application
Cancer
Immunodeficiency
Others
By Region
North America
The U.S.
Canada
Mexico
Europe
Western Europe
The UK
Germany
France
Italy
Spain
Rest of Western Europe
Eastern Europe
Poland
Russia
Rest of Eastern Europe
Asia Pacific
China
India
Japan
Australia & New Zealand
ASEAN
Rest of Asia Pacific
Middle East & Africa (MEA)
UAE
Saudi Arabia
South Africa
Rest of MEA
South America
Brazil
Argentina
Rest of South America

OUR CLIENTS

500 N Michigan Ave, Suite 600, Chicago, Illinois 60611, UNITED STATES
+18882123539
sales@reportocean.com